<DOC>
	<DOCNO>NCT01946035</DOCNO>
	<brief_summary>Allergic rhinitis ( allergic inflammation nose ) common medical condition know seriously decrease quality life , aggravate preexisting condition particularly asthma , carry significant medical treatment cost responsible reduced work productivity lose school day . A significant symptom condition , nasal blockage , remain difficult treat even use nasal corticosteroid . Decongestant medication act blood vessel nose immediate effect clearing block nose use seven day severe rebound congestion nose develops . In study , investigator aim assess effect doxazosin , drug currently use treat high blood pressure symptom prostate enlargement , find effect nasal blockage .</brief_summary>
	<brief_title>Alpha-Blockers Allergic Rhinitis ( MAN 01 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<criteria>Male female 1870 year Able provide inform consent Able comply requirement protocol Diagnosis allergic rhinitis Peak nasal inspiratory flow reversible &gt; 20 l/min oxymetazoline Positive skin prick test least one common aeroallergen Ability withhold antihistamine , intranasal corticosteroid duration study Agreement GP make aware study participation receive feedback relevant participant 's well Pregnancy , plan pregnancy lactation Respiratory tract infection previous 2 month Nasal polyp Grade I nasal endoscopy Any known adverse reaction Investigational Medicinal Product quinazolines Systolic BP &lt; 100mmHg Any degree heart block Any clinically significant medical condition may endanger health safety participant jeopardise protocol Participation within another clinical trial investigational medicinal product within last 30 day Under age 18 Benign hyperplasia , chronic urinary tract infection , bladder stone , overflow bladder , anuria progressive renal failure History oesophageal gastrointestinal obstruction decrease lumen diameter gastrointestinal tract . Concomitant use PDE5 inhibitor ( sildenafil etc . ) Alpha antagonist medication investigation . Other cardiovascular medication include limited : ACE inhibitor , Angiotensin II antagonist , Beta blocker , calcium channel blocker , diuretic , nitrate , phosphodiesterase type5 inhibitor vasodilating medication combination doxazosin carry increase risk symptomatic hypotension . Monoamine oxidase inhibitor ( MAOIs ) antidepressant medication lead significant hypotension combination alpha antagonist . Anxiolytics hypnotic enhance hypotensive sedative effect alphablockers give combination . Methyldopa levodopa potential enhance hypotensive effect alpha antagonist . Nasal corticosteroid spray would confound study outcome Oxymetazoline use outcome response study . Antihistamines participant undergo histamine nasal challenge . Sympathomimetics i.e . dopamine , ephedrine , epinephrine , metaraminol , methoxamine , phenylephrine may reduce effect doxazosin . Any medication , opinion Investigator may put participant risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>